<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01547897</url>
  </required_header>
  <id_info>
    <org_study_id>SNOXE36C301</org_study_id>
    <secondary_id>2011-005710-11</secondary_id>
    <nct_id>NCT01547897</nct_id>
  </id_info>
  <brief_title>NOX-E36 in Patients With Type 2 Diabetes Mellitus and Albuminuria</brief_title>
  <official_title>A Phase IIa Study to Characterize the Effects of CCL2 Inhibition With the Spiegelmer® NOX-E36 in Patients With Type 2 Diabetes Mellitus and Albuminuria</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NOXXON Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NOXXON Pharma AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary objective:

      - To characterize the effects of 12 weeks treatment with study drug on albumin-creatinine
      ratio (ACR) in patients with type 2 diabetes and albuminuria

      Secondary objectives:

        -  To characterize the effect of study drug on glycosylated hemoglobin fraction (HbA1c)

        -  To evaluate the effect of study drug on markers of glycemic disorders, systemic
           inflammation, renal and liver disease and cardiovascular function

        -  To assess the safety and tolerability of study drug

        -  To determine the population pharmacokinetics (PK) of study drug
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2012</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of NOX-E36 on albuminuria as measured by ACR (albumin to creatinine ratio; mg/g)</measure>
    <time_frame>Change versus baseline after 12 weeks treatment</time_frame>
    <description>ACR calculated in first morning void urine; comparison of patients treated with NOX-E36 versus placebo</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of NOX-E36 on hsCRP</measure>
    <time_frame>Change versus baseline after 12 weeks treatment</time_frame>
    <description>Comparison of patients treated with NOX-E36 versus placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of NOX-E36 on HbA1C</measure>
    <time_frame>Change versus baseline after 12 weeks treatment</time_frame>
    <description>Comparison of patients treated with NOX-E36 versus placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of NOX-E36 on HOMA-IR</measure>
    <time_frame>Change versus baseline after 12 weeks treatment</time_frame>
    <description>Comparison of patients treated with NOX-E36 versus placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of NOX-E36 on eGFR</measure>
    <time_frame>Change versus baseline after 12 weeks treatment</time_frame>
    <description>eGFR will be calculated by the CKD-EPI equation using creatinine and cystatin C
Comparison of patients treated with NOX-E36 versus placebo</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">76</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <condition>Albuminuria</condition>
  <arm_group>
    <arm_group_label>NOX-E36</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NOX-E36</intervention_name>
    <description>0.5 mg/kg study drug or placebo as SC injections twice a week</description>
    <arm_group_label>NOX-E36</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Type 2 diabetes mellitus according to American Diabetes Association (ADA) definition

          2. Age ≥ 18

          3. HbA1c between 6.0% and 10.5%, inclusive

          4. ACR &gt; 100 mg/g calculated 3 times in first morning void urine, at least 2 of the
             measurements &gt; 100 mg/g

          5. Patients on stable (unchanged medication for at least 3 months) treatment to control
             hypertension, hyperglycemia and (if applicable) dyslipidemia

          6. Stable treatment with angiotensin-converting enzyme inhibitors (ACEi) and/or
             Angiotensin II receptor blockers (ARBs) (renin-angiotensin system [RAS] blockade)

          7. Willing and able to understand and sign an approved Informed Consent form

          8. Men must agree to follow accepted birth control methods during treatment and for 3
             months after completion of treatment. Women must be of non-childbearing potential.

        Exclusion Criteria:

          1. Type 1 diabetes mellitus

          2. Estimated Glomerular Filtration Rate (eGFR) ≤25 mL/min/1.73m2 (calculated by the
             Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI] formula)

          3. Recent cardiovascular events (3 months)

          4. Uncontrolled hypertension (upper limits 180/110 mmHg)

          5. Dialysis and/or acute kidney injury within 3 months before screening

          6. Significant edema, infectious diseases, leg ulcers

          7. Severe concurrent disease which, in the judgment of the investigator, would interfere
             significantly with the assessments of safety and efficacy during this study

          8. Treatment with any other investigational agent, or participation in another clinical
             study within 90 days prior to baseline visit

          9. Patient with known infection with human immunodeficiency virus (HIV), Hepatitis B or
             Hepatitis C

         10. In the judgment of the clinical investigator, clinically significant abnormal
             laboratory values at the screening visit

         11. Use of thiazolidinedione class drugs, immune suppressants, steroid therapy (except for
             topical use or inhalation), chronic use of non-steroidal anti-inflammatory drug
             (NSAIDs), cyclooxygenase type 2 (COX-2) inhibitors, two or more diuretic drugs and/or
             aliskiren

         12. In the judgment of the clinical investigator, patients who are likely to be
             non-compliant or uncooperative during the study.

         13. Previous participation in this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kai Riecke, MD</last_name>
    <role>Study Director</role>
    <affiliation>Noxxon AG</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Praha</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aschaffenburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dortmund</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Düsseldorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kronberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mannheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Offenbach</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Schwabenheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Witten</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Balatonfüred</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gyula</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miskolc</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pecs</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Szeged</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bialystok</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Grodzisk Mazowiecki</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Katowice</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Arad</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Timisoara</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czech Republic</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Poland</country>
    <country>Romania</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 27, 2012</study_first_submitted>
  <study_first_submitted_qc>March 5, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 8, 2012</study_first_posted>
  <last_update_submitted>February 21, 2014</last_update_submitted>
  <last_update_submitted_qc>February 21, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 24, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Albuminuria</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

